美国食品和药物管理局批准了新冠状动脉疾病诊断工具Flyrcado. GE HealthCare receives FDA approval for new coronary artery disease diagnostic tool, Flyrcado.

美国食品和药物管理局批准了GE HealthCare的Flyrcado (flurpiridaz F 18),这是一种新的PET心肌 perfusion成像剂,用于诊断冠状动脉疾病 (CAD). GE HealthCare has received FDA approval for Flyrcado (flurpiridaz F 18), a new PET myocardial perfusion imaging agent aimed at diagnosing coronary artery disease (CAD). 这种非侵入性诊断工具提高了传统SPECT成像的功效,并可能提高病人的可及性和准确性。 This non-invasive diagnostic tool offers improved efficacy over traditional SPECT imaging and may enhance accessibility and accuracy for patients. Flyrcado可以在未来几年为GE HealthCare的销售增长0.3%至0.6%。 With CAD affecting over 18 million adults in the U.S., Flyrcado could contribute to GE HealthCare's sales growth by 0.3% to 0.6% in the coming years.